Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial

Multiple myeloma (MM) is a plasma cell malignancy expressing B cell maturation antigen (BCMA). Elranatamab, a bispecific antibody, engages BCMA on MM and CD3 on T cells. The MagnetisMM-1 trial evaluated its safety, pharmacokinetics and efficacy. Primary endpoints, including the incidence of dose-lim...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahlis, Nizar J., Costello, Caitlin L., Raje, Noopur S., Levy, Moshe Y., Dholaria, Bhagirathbhai, Solh, Melhem, Tomasson, Michael H., Damore, Michael A., Jiang, Sibo, Basu, Cynthia, Skoura, Athanasia, Chan, Edward M., Trudel, Suzanne, Jakubowiak, Andrzej, Gasparetto, Cristina, Chu, Michael P., Dalovisio, Andrew, Sebag, Michael, Lesokhin, Alexander M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579053/
https://www.ncbi.nlm.nih.gov/pubmed/37783970
http://dx.doi.org/10.1038/s41591-023-02589-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579053/
https://www.ncbi.nlm.nih.gov/pubmed/37783970
http://dx.doi.org/10.1038/s41591-023-02589-w

Ejemplares similares